JPH0372493A - Production of 2'-o-substituted-adenosine-3',5'-cyclic phosphoric acid or its salt - Google Patents
Production of 2'-o-substituted-adenosine-3',5'-cyclic phosphoric acid or its saltInfo
- Publication number
- JPH0372493A JPH0372493A JP20563189A JP20563189A JPH0372493A JP H0372493 A JPH0372493 A JP H0372493A JP 20563189 A JP20563189 A JP 20563189A JP 20563189 A JP20563189 A JP 20563189A JP H0372493 A JPH0372493 A JP H0372493A
- Authority
- JP
- Japan
- Prior art keywords
- camp
- salt
- formula
- adenosine
- dissolved
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 20
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 title claims abstract 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 title claims abstract 3
- 238000004519 manufacturing process Methods 0.000 title description 8
- 150000003983 crown ethers Chemical class 0.000 claims abstract description 9
- 150000004820 halides Chemical class 0.000 claims abstract description 9
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims abstract description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 3
- 125000005843 halogen group Chemical group 0.000 claims abstract 2
- 239000000126 substance Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 2
- 229910001413 alkali metal ion Inorganic materials 0.000 claims description 2
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 claims description 2
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 13
- 150000001875 compounds Chemical class 0.000 abstract description 11
- 239000003513 alkali Substances 0.000 abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 abstract description 2
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 229910021645 metal ion Inorganic materials 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 235000002639 sodium chloride Nutrition 0.000 description 20
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 18
- 239000002904 solvent Substances 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 239000013078 crystal Substances 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- -1 alkali metal salt Chemical class 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 238000000921 elemental analysis Methods 0.000 description 6
- 235000011118 potassium hydroxide Nutrition 0.000 description 6
- 159000000000 sodium salts Chemical class 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- 150000003863 ammonium salts Chemical class 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 101710170231 Antimicrobial peptide 2 Proteins 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- VFTFKUDGYRBSAL-UHFFFAOYSA-N 15-crown-5 Chemical compound C1COCCOCCOCCOCCO1 VFTFKUDGYRBSAL-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102220506674 MKRN2 opposite strand protein_H26N_mutation Human genes 0.000 description 1
- 241001467578 Microbacterium Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- NAMOQHUSOPIBPH-UHFFFAOYSA-N [Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[NH4+].[NH4+].[NH4+].[NH4+].[NH4+].[NH4+].[NH4+] Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[NH4+].[NH4+].[NH4+].[NH4+].[NH4+].[NH4+].[NH4+] NAMOQHUSOPIBPH-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000006289 hydroxybenzyl group Chemical group 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 125000006178 methyl benzyl group Chemical group 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006502 nitrobenzyl group Chemical group 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、2′−〇−置換−7デノ/ンー3′、5L環
状り7m(以下2′−〇−置換−cAMP という)
又はその塩の新規な製法に関する。Detailed Description of the Invention [Industrial Application Field] The present invention provides 2'-〇-substituted-7deno/-3',5L cyclic 7m (hereinafter referred to as 2'-〇-substituted-cAMP).
or a new method for producing the salt thereof.
アデノシン−3’、 5’−環状リン酸(以下cAMP
という)及びその誘導体は、種々の生理活性を有し、生
化学的試薬や医薬としているいろな用途が期待されてい
る。本化合物は抗炎症作用、血小板凝集阻害作用、血圧
降下作用などの優れた薬理作用を有すると目される有用
なものである。Adenosine-3', 5'-cyclic phosphate (hereinafter cAMP)
) and its derivatives have various physiological activities and are expected to have a variety of uses as biochemical reagents and medicines. This compound is considered to be useful as having excellent pharmacological effects such as anti-inflammatory effect, platelet aggregation inhibiting effect, and blood pressure lowering effect.
2′−O−メチル−cAMP の製法として、2′−〇
−メチルアデノシンを原料とし、オキ/塩化すンヲ作用
させて2’−0−メチルアデノシン−57−フォスフェ
ートとし、次いで4−モルフォリン−N、N’−ジンク
−ヘキシルカルボキサミジンを作用させて連化する方法
(バイオケミストリー、12巻、1010〜1016頁
(1973年))、cAMP にフルカリ水溶液中でヨ
ウ化メチルを作用させる方法(バイオケミストリー
11巻、4931〜4937頁(1972年))などが
知られている。The method for producing 2'-O-methyl-cAMP is to use 2'-0-methyladenosine as a raw material, react with oxygen/chloride to form 2'-0-methyladenosine-57-phosphate, and then convert 4-morpholine into 2'-0-methyladenosine-57-phosphate. -N,N'-zinc-hexylcarboxamidine (Biochemistry, Vol. 12, pp. 1010-1016 (1973)); A method of reacting cAMP with methyl iodide in an aqueous Flukali solution. (Biochemistry
11, pp. 4931-4937 (1972)).
上記の方法では、いずれも操作が煩雑であるとか、中鎖
や長鎖のアルキル基で2’ −OH基を置換することが
できない。In all of the above methods, the operations are complicated, and the 2'-OH group cannot be substituted with a medium-chain or long-chain alkyl group.
本発明者らは、これらの欠点を解消すべく鋭意研究した
結果% CAMP 又はその塩をアルカリ及びクラ
ウンエーテル存在下で有機ハロゲン化物と反応させるこ
とにより、中鎖、長鎖のアルキル基でも、cAMP 又
はその塩の2’−OH基を容易に効率良く置換し得るこ
とを見出し、この知見に基づいて本発明を完成した。As a result of intensive research aimed at solving these drawbacks, the present inventors found that by reacting CAMP or a salt thereof with an organic halide in the presence of an alkali and a crown ether, cAMP can be obtained even with medium-chain and long-chain alkyl groups. or its salt can be easily and efficiently substituted, and based on this knowledge, the present invention was completed.
すなわち本発明は、
一般式
機ハロゲン化物と反応させることを特徴とする、−紋穴
(式中Aのは水素イオン、アルカリ金属イオン、アルカ
リ土類金属イオン、アンモニウムイオン又は有機アンモ
ニウムイオンを示す)で表わされるcAMP 又はそ
の塩を、アルカリ条件下、かつクラウンエーテル存在下
で、−紋穴
%式%()
(式中Rはアルキル基又はアラアルキル基ヲ示し、Xは
ハロゲン原子を示す)で表わされる有(式中R及びAG
)は前記の意味を有する)で表わされる2′−〇−置換
−cAMP 又はその塩の製法である。That is, the present invention is characterized by reacting with a general formula halide (in the formula, A represents a hydrogen ion, an alkali metal ion, an alkaline earth metal ion, an ammonium ion, or an organic ammonium ion). cAMP or a salt thereof represented by the following formula is added under alkaline conditions and in the presence of crown ether: (in the formula R and AG
) has the above meaning) is a method for producing 2'-0-substituted-cAMP or a salt thereof.
以下、本発明について詳しく説明する。The present invention will be explained in detail below.
本発明の出発物質として用いられるcAMP 又はその
塩は、例えば次のようにして製造される。cAMP or a salt thereof used as a starting material in the present invention is produced, for example, as follows.
アデニン、キシロース若しくはリポース及び無機リン酸
塩を含む培地を用いて、ミクロバクテリウム属に属し、
アデニン、キシロース若シ<ハリボース及び無lilリ
ン酸塩とからcAMP を生産する能力を6する菌を培
養し、培養物よりcAMPを特徴する特許第65178
1号明細書参照)。belonging to the genus Microbacterium using a medium containing adenine, xylose or lipose and inorganic phosphate,
Patent No. 65178, which involves culturing a bacterium that has the ability to produce cAMP from adenine, xylose, halibose, and free phosphate, and producing cAMP from the culture.
(See specification No. 1).
またcAMP 又はその塩は合成法などによっても得
られる。Furthermore, cAMP or its salt can also be obtained by synthetic methods.
又は遊離のcAMP にアルカリ金属又はアルカリ土
類金属の水酸化物、炭酸塩、炭酸水素塩なト、するいは
有機アミン好ましくはトリアルキルアミンを作用させる
と、cAMP のリン酸部におけるアルカリ金属塩、
例えばナトリウム塩、カリウム塩など、アルカリ土類金
属塩、例えばカルシウム塩、マグネシウム塩など、有機
アンモニウム塩、例エバトリエチルアンモニウム塩、ア
ンモニウム塩等を得ることができる。Alternatively, when free cAMP is treated with an alkali metal or alkaline earth metal hydroxide, carbonate, hydrogen carbonate, or an organic amine, preferably a trialkylamine, an alkali metal salt in the phosphate moiety of cAMP is formed. ,
For example, sodium salts, potassium salts, alkaline earth metal salts, such as calcium salts, magnesium salts, etc., organic ammonium salts, such as evatriethylammonium salts, ammonium salts, etc. can be obtained.
一般式(1)で表わされる有機ハロゲン化物のRとして
は、炭素数l〜16、好ましくは3〜14のアルキル基
、例えばメチル基、エチル基、プロピル基、ブチル基、
ペンチル基、ヘキシル基、ヘプチル基、オクチル基、ノ
ニル基、デシル基、ウンデノル基、ドデシル基、トリテ
シル火、テトラデシル基、ペンタデシル基、ヘキサデシ
ル基などの直鎖状若しくはそれらの分枝状のアルキル基
、アラアルキル基、例えばベンジ/l&i、ニトロベン
ジル基、りpロベンジル基、メチルベンジル基、ハイド
ロキシベンジル基、アミノベンジル基、フェネチル基、
フェニルプロピル基などが挙げられる。As R of the organic halide represented by the general formula (1), an alkyl group having 1 to 16 carbon atoms, preferably 3 to 14 carbon atoms, such as a methyl group, an ethyl group, a propyl group, a butyl group,
Straight chain or branched alkyl groups such as pentyl group, hexyl group, heptyl group, octyl group, nonyl group, decyl group, undenol group, dodecyl group, tritecyl group, tetradecyl group, pentadecyl group, hexadecyl group, aralkyl groups, such as benzyl/l&i, nitrobenzyl group, polybenzyl group, methylbenzyl group, hydroxybenzyl group, aminobenzyl group, phenethyl group,
Examples include phenylpropyl group.
一般式([I)で表わされるcAMP 又はその塩と一
般式(1)で表わされる有機ハロゲン化物との反応は、
アルカリ条件下で、かつ、クラウンエーテル存在下で行
なわせる。The reaction between cAMP represented by the general formula ([I) or its salt and the organic halide represented by the general formula (1)]
The reaction is carried out under alkaline conditions and in the presence of crown ether.
アルカリとしては、例えば水酸化ナトリウム、水酸化カ
リウム、水酸化カルシウム、炭酸ナトリウム、炭酸カリ
ウム、炭酸水素ナトリウム、炭酸水素カリウム、炭酸水
素カルシウム、水素化ナトリウム、水素化カリウムなど
のアルカリ金属又はアルカリ土類金属の水酸化物、炭酸
塩、炭酸水素塩、水素化物、あるいは、例えばナトリウ
ムメトキシドなどのアルコキサイドなどが単独又は組み
合わせて用いられる。Examples of alkalis include alkali metals or alkaline earths such as sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, calcium hydrogen carbonate, sodium hydride, and potassium hydride. Metal hydroxides, carbonates, hydrogen carbonates, hydrides, or alkoxides such as sodium methoxide are used alone or in combination.
またクラウンエーテルとしては、例えば18−クラウン
−6,15−クラウン−5などが用いられる。Further, as the crown ether, for example, 18-crown-6, 15-crown-5, etc. are used.
この反応は溶媒中で行なわれる。溶媒としては水、メタ
/−ル、エタノールなどのアルコール類、ンオキサン、
テトラヒドロフランなどのエーテル類、ジメチルホルム
アミド、ジメチルアセトアミドなどのアミド類、酢酸エ
チルなどの有機カルボン酸のエステル類、ジメチルスル
ホキサイドなどが単独又は2種以上の混合物として適宜
用いられる。This reaction takes place in a solvent. As a solvent, water, alcohols such as methanol, ethanol, oxane,
Ethers such as tetrahydrofuran, amides such as dimethylformamide and dimethylacetamide, esters of organic carboxylic acids such as ethyl acetate, dimethyl sulfoxide, and the like may be used individually or as a mixture of two or more as appropriate.
一般式(Q)で表わされるcAMP 又はその塩に対す
る一般式(厘)で表わされる有機ハロゲン化物の使用量
は、通常1〜20倍モル、好ましくは 1〜lO@モル
である。また、−紋穴([l)で表わされるcAMP
又はその塩に対するアルカリの使用量は、通常2〜2
0倍モル、好ましくは5〜10倍モルであり、クラウン
エーテルの使用量は、通常0.5〜20倍モル、好まし
くはt−to@そルである。The amount of the organic halide represented by the general formula (厘) to be used is usually 1 to 20 times the molar amount of cAMP represented by the general formula (Q) or its salt, preferably 1 to 10@molar. In addition, cAMP represented by -monana ([l)
Or the amount of alkali used for the salt is usually 2 to 2.
The amount of crown ether used is usually 0.5 to 20 times, preferably t-to@solu.
この反応は通常は用いる溶媒の沸点以下で行なわれるが
、一般に10〜150 ’C、好ましくは40〜lOO
℃の温度において、静置若しくは撹拌下に1時間以上、
好ましくは1時間〜4日間行なわれる。This reaction is usually carried out at a temperature below the boiling point of the solvent used, generally from 10 to 150'C, preferably from 40 to 100'C.
At a temperature of ℃, for 1 hour or more while standing or stirring,
It is preferably carried out for 1 hour to 4 days.
一般式(1)で表わされる目的化合物の2′−O−置換
−cAMP 又はその塩を単離、精製するには、例えば
シリカゲル、アルミナ、イオ74[1脂、活性炭などを
用いるカラムクロマトグラフィ、再結晶法、pH調整に
よる析出法、食塩を用いる塩析法、有機溶媒を用いる油
出法などの精製法が単独で又は適宜組み合わぜて用いら
れる。In order to isolate and purify the target compound 2'-O-substituted-cAMP represented by general formula (1) or a salt thereof, for example, column chromatography using silica gel, alumina, io-74[1 fat, activated carbon, etc. Purification methods such as a crystallization method, a precipitation method by pH adjustment, a salting-out method using common salt, and an extraction method using an organic solvent may be used alone or in appropriate combinations.
なお、目的化合物の他にNcl、2LO−ジ置換−cA
MP カ生成する場合もあるが、このときの分離精製法
としては、例えばシリカゲルのカラムや薄層クロマトグ
ラフィ(展開溶媒;メタノール/クロロホルムなど)な
どを用いればよい。またシリカゲル薄層クロマトグラフ
ィを用いる際には、そのRf値は2′−〇−置換−cA
MP に比し、N’、2’−0−ジ置換−cAMP
が大となる。In addition to the target compound, Ncl, 2LO-disubstituted-cA
In some cases, MP powder may be produced, and as a separation and purification method in this case, for example, a silica gel column or thin layer chromatography (developing solvent: methanol/chloroform, etc.) may be used. Furthermore, when using silica gel thin layer chromatography, the Rf value is 2'-〇-substituted-cA
Compared to MP, N',2'-0-disubstituted-cAMP
becomes large.
−紋穴(1)で表わされるcAMP の遊離酸に、例
え+iアルカリ金属又はアルカリ土類金属の水酸化物、
炭酸塩、炭酸水素塩、あるいはアンモ二7又は有taア
ミン、例えハトリエチルアミン、トリブチルアミンたど
の三級アミンを作用させることにより、環状リン酸部を
対応する塩に導くことができる。- The free acid of cAMP represented by the pattern (1), for example +i alkali metal or alkaline earth metal hydroxide,
The cyclic phosphoric acid moiety can be converted to the corresponding salt by the action of a carbonate, a hydrogen carbonate, or a tertiary amine such as ammonia or a ta-amine, such as triethylamine or tributylamine.
本発明により得られる一般式(I)で表わされる2’−
〇−置換−cAMP 及びその塩の例としては、次の
ものが挙げられる。2'- represented by general formula (I) obtained by the present invention
Examples of 〇-substituted-cAMP and its salts include the following.
2′−〇−メチルーcAMP 2’−0−zチル−
cAMP2’−0−プロピル−cAMP 2’
O−ブチル−cAMP 2’ −Q−ペンチル−c
AMP2′−〇−へキシル−cAMP 2’ −0
−へブチル−cAMP 2’ −0−オクチル−c
AMP 2’ −0−ノニル−cAMP2’−0−
デシル−cAMP2′−〇−ウンデシルーcAMP2’
−0−ドデンルーcAMP2’−0−トリデシル−cA
MP2′−〇−テトラデシルーcAMP2’−0−ペン
タデシル−cAMP 2’ −0−へキサデンルー
CAMP %若しくはこれらのアルキル基の分枝状の
もの、2′−〇−ベンジルーcAMP 2’ −0
−ニドpベンジルーcAMP 2’ −Q−クロロ
ベンジルCAMP % 2’ Q iチルベンジル
−cAMP2’−0−ハイドロキシベンジル−cAMP
2’ −O−アミノベ/ジル−cAMP 2
’−〇 −2−フェニルエチル−cAMP 、 2’
−0−3〜フェニルプpビル−CAMP %並びにこれ
らのアルカリ金属塩、アルカリ土類金属塩、アンモニウ
ム塩及び有機アンモニウム塩など。2'-〇-methyl-cAMP 2'-0-zthyl-
cAMP2'-0-propyl-cAMP2'
O-butyl-cAMP 2'-Q-pentyl-c
AMP2'-〇-hexyl-cAMP2'-0
-hebutyl-cAMP 2' -0-octyl-c
AMP2'-0-nonyl-cAMP2'-0-
Decyl-cAMP2'-〇-undecyl-cAMP2'
-0-dodenru-cAMP2'-0-tridecyl-cA
MP2'-〇-tetradecyl-cAMP2'-0-pentadecyl-cAMP 2'-0-hexadenyl-CAMP% or branched versions of these alkyl groups, 2'-〇-benzyl-cAMP 2'-0
-nido pbenzyl-cAMP 2' -Q-chlorobenzyl CAMP % 2' Q i thylbenzyl-cAMP2'-0-hydroxybenzyl-cAMP
2'-O-aminobe/dyl-cAMP 2
'-〇 -2-phenylethyl-cAMP, 2'
-0-3~Phenylpvir-CAMP% and their alkali metal salts, alkaline earth metal salts, ammonium salts, organic ammonium salts, etc.
本発明によれば、従来の方法では、cAMP の2’−
OH基に導入することができない中鎖、長鎖のアルキル
基でも、極めて容易に導入することができる。According to the present invention, in the conventional method, the 2'-
Even medium-chain and long-chain alkyl groups that cannot be introduced into OH groups can be introduced very easily.
本発明は、例えば抗炎症作用、血小板凝集阻害作用、血
圧降下作用などの優れた薬理作用を有すると目される有
用な2’−0−置換−cAMP 又はその塩を極めて効
率よく製造することができるものであり、産業上非常に
有意義にものである。The present invention enables extremely efficient production of useful 2'-0-substituted-cAMP or its salts, which are expected to have excellent pharmacological effects such as anti-inflammatory effects, platelet aggregation inhibiting effects, and antihypertensive effects. It is possible to do so, and is of great industrial significance.
以下、実施例により本発明を具体的に説明するO
実施例1
2′−〇−プロピルーcAMP のナトリウム塩の製造
水酸化カリウム5.28 gを溶解した水溶液30dt
こ、cAMP 3.299を溶解し、これに18−ク
ラウン−6を7.93g溶解したジオキサン150−を
添加する。次いで、n−プμピルブロマイド5.45−
を添加し、水浴中50℃で6時間撹拌する。反応液を2
N−塩酸で中和した後、溶媒を減圧留去する。残留する
油状物質を少量の水に溶解し、2N−塩酸を加えてpH
2に調整し、粗結晶を得る。得られた粗結晶に少量のメ
タノールを加え、 2N−水酸化ナトリウムを添加して
溶解し、これをシリカゲル薄層クロマトグラフィ 〈展
開ew;メタノール/クロロホルム、容量比:1:1〉
に・より分離精製し、目的化合物のUV 吸収帯(Rf
値0.57付近)をかぎ取り、メタノールで抽出し減圧
乾固すると、2’−0−プロピル−cAMP のナトリ
ウム塩が1.38 g (収率37.5%)得られた。Hereinafter, the present invention will be specifically explained with reference to Examples.
3.299 cAMP was dissolved, and dioxane 150- in which 7.93 g of 18-crown-6 was dissolved was added. Then, n-pyl bromide 5.45-
and stirred in a water bath at 50° C. for 6 hours. 2 of the reaction solution
After neutralizing with N-hydrochloric acid, the solvent was distilled off under reduced pressure. Dissolve the remaining oily substance in a small amount of water and adjust the pH by adding 2N-hydrochloric acid.
2 to obtain crude crystals. A small amount of methanol was added to the obtained crude crystals, 2N-sodium hydroxide was added and dissolved, and this was subjected to silica gel thin layer chromatography (Development: methanol/chloroform, volume ratio: 1:1)
The target compound is separated and purified by UV absorption band (Rf
(value around 0.57) was extracted with methanol and dried under reduced pressure to obtain 1.38 g (yield: 37.5%) of the sodium salt of 2'-0-propyl-cAMP.
この一部を水に溶解し、次いで2N−塩酸でpH2とし
、再結晶を行なった。A portion of this was dissolved in water, then adjusted to pH 2 with 2N hydrochloric acid, and recrystallized.
元素分析値: C’+ 3H+ sN 50 aP・
5/4H20として
測定値(%〉
計算値(%〉
39.92
39.65
5.16
5.25
17.53
17.78
UV : λ ’Q二’:: ”0H(g )
258 (13200) nmRf [: 0.
42 (シリカゲル薄層りμマドグラフィ(展開溶媒
; 0.IN 塩化7ンモニウム:メタノール:アセ
トニトリ
ル、容量比;L:l:5)、以下の実施例においても同
じ〕
実施例2
2′−〇−ブチルーcAMP のナトリウム塩の製造水
酸化カリウム 1.01.9を溶解した水溶液10Jl
/に、cAMP 1.009を溶解し、これに18−
クラウン−6を2.014 g溶解したジオキサン50
−を添加する。次いで、n−ブチルブロマイド1.30
+w/を添加し、水浴中50°Cで2日間撹拌する。反
応液を2N−塩酸で中和した後、溶媒を減圧留去する。Elemental analysis value: C'+ 3H+ sN 50 aP・
Measured value as 5/4H20 (%> Calculated value (%) 39.92 39.65 5.16 5.25 17.53 17.78 UV: λ 'Q2':: "0H (g)
258 (13200) nmRf [: 0.
42 (Silica gel thin layer μmography (developing solvent; 0.IN heptammonium chloride:methanol:acetonitrile, volume ratio: L:l:5), the same applies to the following examples) Example 2 2'-〇-Butyl Preparation of sodium salt of cAMP 10 Jl of an aqueous solution of potassium hydroxide 1.01.9
Dissolve cAMP 1.009 in / and add 18-
Dioxane 50 in which 2.014 g of Crown-6 was dissolved
− is added. Then n-butyl bromide 1.30
+w/ and stir for 2 days at 50°C in a water bath. After neutralizing the reaction solution with 2N hydrochloric acid, the solvent was distilled off under reduced pressure.
残留する油状物質を少量の水に溶解し、2N−塩酸を加
えて pH2に調整し、粗結晶を得る。得られた粗結晶
に少量のメタノールを加え、 2N−水酸化ナトリウム
を添加して溶解し、これをシリカゲル薄層クロマトグラ
フィ(展開溶媒;メタノール/クーロホルム、容量比;
4:6)により分離精製し、目的化合物のUV 吸収帯
(Rf値0.5付近)をかき取り、メタノールで油出し
減圧乾固すると、2′−〇−ブチルーcAMP のナ
トリウム塩が580 s+v (収率49.5%)得ら
れた。The remaining oily substance is dissolved in a small amount of water, and the pH is adjusted to 2 by adding 2N hydrochloric acid to obtain crude crystals. A small amount of methanol was added to the obtained crude crystals, 2N-sodium hydroxide was added and dissolved, and this was subjected to silica gel thin layer chromatography (developing solvent: methanol/couloform, volume ratio;
4:6), scrape off the UV absorption band (Rf value around 0.5) of the target compound, extract the oil with methanol, and dry under reduced pressure to obtain the sodium salt of 2'-〇-butyl-cAMP at 580 s+v ( Yield: 49.5%).
この一部を水に溶解し、次いで2N−塩酸でpH2とし
、再結晶を行なった。A portion of this was dissolved in water, then adjusted to pH 2 with 2N hydrochloric acid, and recrystallized.
元素分析値: C+ aH2ON so 6P・5/
4 H20として
測定値(%)
計算値(%)
41.29
41.23
N
5.29 16.90
5.56 L7.L7
UV : λ Q二iN N・0H(t )
258 (14100) nmRf値:0.44
実施例3
2′−〇−ベンチルーcAMP の製造水酸化カリウム
5.28 yを溶解した水溶液30m1に、cAMP
3.29 gを溶解し、これに18−クラウン−6を
7.93 F溶解したジオキサン150−を添加する。Elemental analysis value: C+ aH2ON so 6P・5/
4 Measured value (%) as H20 Calculated value (%) 41.29 41.23 N 5.29 16.90 5.56 L7. L7 UV: λ Q2iN N・0H(t)
258 (14100) nmRf value: 0.44 Example 3 Production of 2'-〇-benzene cAMP To 30 ml of an aqueous solution in which 5.28 y of potassium hydroxide was dissolved, cAMP was added.
3.29 g was dissolved, and dioxane 150- in which 18-crown-6 was dissolved at 7.93 F was added thereto.
次いで、n 7 ミルブロマイド7.41−を添加し
、水浴中50℃で2日間撹拌する。反応液を2N−塩酸
で中和した後、溶媒を減圧留去する0残留する油状物質
を少量の水に溶解し、2N−塩酸を加えてpH2に調整
し、これを活性炭カラム(2,2x 21 cn)に吸
着させ、水洗後、メタノール/水/28%水酸化アンモ
ニウム(容量比; 10: to: l)を用いて溶
出する区分を採取し、これを減圧乾固する。得られたカ
ラメル状物質を少量のメタノールに溶解し、これをシリ
カゲル薄層クロマトグラフィ (展開溶媒;メタノール
/クローホルム、容量比:35:65)により分離精製
し、目的化合物の画吸収帯(Rf値0.3付近)をかき
取り、メタノールで抽出し減圧乾固する。これを水に溶
解し、次いで2N−塩酸で pH2に調整すると、2L
O−ベンチルーcAMP の結晶1.13 g(収率2
8.8%)が得られた。7.41- of n7 milbromide is then added and stirred for 2 days at 50<0>C in a water bath. After neutralizing the reaction solution with 2N-hydrochloric acid, the solvent was distilled off under reduced pressure.The remaining oily substance was dissolved in a small amount of water, the pH was adjusted to 2 by adding 2N-hydrochloric acid, and this was transferred to an activated carbon column (2, 2x After washing with water, the fraction eluted with methanol/water/28% ammonium hydroxide (volume ratio: 10: to: l) is collected and dried under reduced pressure. The obtained caramel-like substance was dissolved in a small amount of methanol, and this was separated and purified by silica gel thin layer chromatography (developing solvent: methanol/chloroform, volume ratio: 35:65), and the absorption band of the target compound (Rf value 0) was separated and purified. .3) was scraped off, extracted with methanol, and dried under reduced pressure. Dissolve this in water and then adjust the pH to 2 with 2N hydrochloric acid, resulting in 2L
1.13 g of O-benzene-cAMP crystals (yield: 2
8.8%) was obtained.
元素分析値:Cl5H2□N 50 ap−1/2 H
20として
HN
測定値(%) 44.07 5.69 17.26計
算値(%) 44,12 5.68 17.15Uv
: λ ’=4P: ”H(t ) 258
(14500) nmRf [: 0.46
実施例4
2′−〇−ヘプチルーcAMP のナトリウム塩の製カ
コ
水酸化カリウム2.64 gを溶解した水溶液15−に
、cAMP 1.65 pを溶解し、これに18−ク
ラウン−6を3.97 、p溶解したジオキサン75屑
eを添加する。次いで、n−へブチルブロマイド4.7
0Jl/を添加し、水浴中60°Cで1日間撹拌する。Elemental analysis value: Cl5H2□N 50 ap-1/2 H
HN as 20 Measured value (%) 44.07 5.69 17.26 Calculated value (%) 44.12 5.68 17.15 Uv
: λ'=4P: ”H(t) 258
(14500) nmRf [: 0.46 Example 4 Preparation of sodium salt of 2'-〇-heptyl-cAMP 1.65 p of cAMP was dissolved in an aqueous solution 15 in which 2.64 g of potassium hydroxide was dissolved. Add 3.97 g of 18-crown-6 and 75 g of dissolved dioxane. Then n-hebutyl bromide 4.7
Add 0 Jl/ and stir for 1 day at 60°C in a water bath.
反応液を2N−塩酸で中和した後、溶媒を減圧留去する
。残留する油状物質を少量の水に溶解し、2N−塩酸を
加えてpH2に調整し、粗結晶を得る。得られた粗結晶
に少量のメタノールを加え、 2N−水酸化ナトリウム
を添加して溶解し、これを7リ力ゲル薄層クロマトグラ
フィ (展開溶媒;メタノール/りローホルム、容量比
;35 : 65)により分離精製し、目的化合物の四
吸収帯(Rf値0.4付近)をかき取り、メタノールで
抽出し減圧乾固すると、2’−0−へブチル−cAMP
のナトリウム塩が1.34g(収率62.6%)得ら
れた。After neutralizing the reaction solution with 2N hydrochloric acid, the solvent was distilled off under reduced pressure. The remaining oily substance is dissolved in a small amount of water, and the pH is adjusted to 2 by adding 2N hydrochloric acid to obtain crude crystals. A small amount of methanol was added to the obtained crude crystals, and 2N-sodium hydroxide was added to dissolve the crystals, which was then subjected to 7L gel thin layer chromatography (developing solvent: methanol/liroform, volume ratio: 35:65). After separating and purifying the target compound, scraping off the four absorption bands (Rf value around 0.4), extracting with methanol and drying under reduced pressure, 2'-0-hebutyl-cAMP is obtained.
1.34 g (yield 62.6%) of the sodium salt of was obtained.
この一部を水に溶解し、次いで2N−塩酸でpH2とし
、再結晶を行なった。A portion of this was dissolved in water, then adjusted to pH 2 with 2N hydrochloric acid, and recrystallized.
元素分析値:C1□H26N 50 oP−H20とし
て
HN
測定値(%) 46.12 6.35 15.37計
算値(%) 45.84 6.34 15.72Uv
: λ’;:” ”0H(g ) 258 (13
500) nmRf値:0.49
実施例5
2′−O−テトラデンルーcAMP のトリエチルア
ミン塩の製造
水酸化カリウム5.28.5+を溶解した水溶液30m
eニcAMP 3.291/を溶解し、これニ18−
り5ウンー6を7.93 g溶解したジオキサ7150
mlを添加する。次いで、n−ミ!Jスチルプμマイ
ト17.85 mlを添加し、水浴中50°Cで撹拌す
る。さラニn−ミリスチルブロマイドを3日後に5.9
5m/加えた。さらに反応液を50°Cで2日間撹拌し
た後、反応液を2N−塩酸で中和し、溶媒を減圧留去す
る。残留する油状物質を少量の水に醍解し、2N−塩酸
を加えてpH2に調整し、粗結晶を得た。これにジクロ
ロメタン70!11/ヲ加工、トリエチルアミンを添加
して溶解し、水200dで2回抽出する。ジクロロメタ
ンを少容量に濃縮し、シリカゲル30g(クロロホルム
中に詰める)カラム上にのせる。このカラムをクロロホ
ルムで洗い、メタノール/クロロホルム(容JI比;
1:9〜4:6)を用いて溶出する目的化合物を含む
区分を採取し、これを減圧乾固すると、2’−0−テト
ラテ/ルーcAMP のトリエチルアミン塩が1.1
5 g (収率22%)得られた。Elemental analysis value: HN as C1□H26N 50 oP-H20 Measured value (%) 46.12 6.35 15.37 Calculated value (%) 45.84 6.34 15.72 Uv
: λ';:” ”0H(g) 258 (13
500) nmRf value: 0.49 Example 5 Production of triethylamine salt of 2'-O-tetraden-cAMP 30 ml of an aqueous solution in which 5.28.5+ potassium hydroxide was dissolved
Dissolve e-cAMP 3.291/, and dissolve this di-18-
Dioxa 7150 dissolved in 7.93 g of Ri5un-6
Add ml. Next, n-mi! Add 17.85 ml of J Stirpmite and stir at 50°C in a water bath. Sarani n-myristyl bromide after 3 days 5.9
5m/added. After further stirring the reaction solution at 50°C for 2 days, the reaction solution was neutralized with 2N-hydrochloric acid, and the solvent was distilled off under reduced pressure. The remaining oily substance was dissolved in a small amount of water, and the pH was adjusted to 2 by adding 2N hydrochloric acid to obtain crude crystals. This was treated with dichloromethane 70:11/w, triethylamine was added and dissolved, and the mixture was extracted twice with 200 d of water. Dichloromethane is concentrated to a small volume and loaded onto a 30 g silica gel (packed in chloroform) column. Wash this column with chloroform and methanol/chloroform (volume JI ratio;
1:9 to 4:6) was used to collect the fraction containing the target compound, which was dried under reduced pressure.
5 g (yield 22%) was obtained.
この一部を水に溶解し、次いで2N−塩酸でpH2とし
、再結晶を行なった。A portion of this was dissolved in water, then adjusted to pH 2 with 2N hydrochloric acid, and recrystallized.
元素分析値: C24H4゜N sOaP・ 3/4
H20として
測定値(%)
計算値(%)
53.76
53.47
7.70
7.76
12.76
12.99
UV : λ 〇二二′: ”0H(t ) 2
58 (12000) nmRf値:0.55
実施例6
2′−〇−ベンジルーcAMP の製造水酸化カリウム
1.32 gを溶解した水溶液60yrtに、cAMP
3.29 gを溶解し、これに18−り5 ラフ
−6全2.6417溶解したジオキサン150#Ilを
添加する。次いで、n−ベンジルブロマイド1.19g
/を添加し、室温で1日間撹拌する。反応液を2N−塩
酸で中和した後、溶媒を減圧留去する。残留する油状物
質を少量の水に溶解し、2N−塩酸を加えて pH2に
調整し、粗結晶を得る。得られた粗結晶に少量のメタノ
ールを加え、2N−水酸化ナトリウムを添加して溶解し
、これをシリカゲル薄層りρマドグラフィ (展開溶媒
;メタノール/クロロホルム、容量比;4:6)により
分離精製し、目的化合物の画吸収帯(Rf値0.25付
近)をかき取り、メタノールで抽出し減圧乾固する。こ
れを水に溶解し、次いで2N −塩酸でpH2に調整す
ると、2’−0−ベンジルcAMP の結晶2.12
g (収率50.7%)か得られた。Elemental analysis value: C24H4゜N sOaP・3/4
Measured value (%) Calculated value (%) as H20 53.76 53.47 7.70 7.76 12.76 12.99 UV: λ 〇22': ``0H(t) 2
58 (12000) nmRf value: 0.55 Example 6 Production of 2'-〇-benzy-cAMP cAMP was added to 60 yr of an aqueous solution in which 1.32 g of potassium hydroxide was dissolved.
Dissolve 3.29 g and add 18-5 rough
-6 Add 150 #Il of total 2.6417 dissolved dioxane. Next, 1.19 g of n-benzyl bromide
/ and stir at room temperature for 1 day. After neutralizing the reaction solution with 2N hydrochloric acid, the solvent was distilled off under reduced pressure. The remaining oily substance is dissolved in a small amount of water, and the pH is adjusted to 2 by adding 2N hydrochloric acid to obtain crude crystals. A small amount of methanol was added to the obtained crude crystals, 2N sodium hydroxide was added to dissolve the crystals, and this was separated and purified using a thin layer of silica gel rhomadography (developing solvent: methanol/chloroform, volume ratio: 4:6). Then, the image absorption band of the target compound (Rf value around 0.25) is scraped off, extracted with methanol, and dried under reduced pressure. When this was dissolved in water and the pH was adjusted to 2 with 2N hydrochloric acid, 2'-0-benzyl cAMP crystals were obtained.
g (yield 50.7%) was obtained.
元素分析値: C17H18N so oP・1/2
H20として
H
測定値(%)
47.61
4.23
16.20
計算値(%)
47.67
4.47
16.34
UV : λ 0ニニで
(ε
)
58
(14700)
f
値:0.47Elemental analysis value: C17H18N so oP・1/2
H as H20 Measured value (%) 47.61 4.23 16.20 Calculated value (%) 47.67 4.47 16.34 UV: λ 0 (ε) 58 (14700) f value: 0.47
Claims (1)
ルカリ土類金属イオン、アンモニウムイオン又は有機ア
ンモニウムイオンを示す)で表わされるアデノシン−3
′、5′−環状リン酸又はその塩を、アルカリ条件下、
かつクラウンエーテル存在下で、一般式 RX(III) (式中Rはアルキル基又はアラアルキル基を示し、Xは
ハロゲン原子を示す)で表わされる有機ハロゲン化物と
反応させることを特徴とする、一般式 ▲数式、化学式、表等があります▼( I ) (式中R及びA^■は前記の意味を有する)で表をされ
る2′−O−置換−アデノシン−3′,5′−環状リン
酸又はその塩の製法。(1) General formula ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼ (II) (In the formula, A^■ represents a hydrogen ion, an alkali metal ion, an alkaline earth metal ion, an ammonium ion, or an organic ammonium ion) adenosine-3
',5'-cyclic phosphoric acid or its salt under alkaline conditions.
and in the presence of a crown ether, the general formula is reacted with an organic halide represented by the general formula RX (III) (wherein R represents an alkyl group or an aralkyl group, and X represents a halogen atom). ▲There are mathematical formulas, chemical formulas, tables, etc.▼(I) 2'-O-substituted-adenosine-3',5'-cyclic phosphorus represented by (in the formula, R and A^■ have the above meanings) Process for producing acids or their salts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP20563189A JPH0372493A (en) | 1989-08-10 | 1989-08-10 | Production of 2'-o-substituted-adenosine-3',5'-cyclic phosphoric acid or its salt |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP20563189A JPH0372493A (en) | 1989-08-10 | 1989-08-10 | Production of 2'-o-substituted-adenosine-3',5'-cyclic phosphoric acid or its salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0372493A true JPH0372493A (en) | 1991-03-27 |
Family
ID=16510089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP20563189A Pending JPH0372493A (en) | 1989-08-10 | 1989-08-10 | Production of 2'-o-substituted-adenosine-3',5'-cyclic phosphoric acid or its salt |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0372493A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07103150B2 (en) * | 1990-04-09 | 1995-11-08 | オイロペーイッシェス ラボラトリウム フュア モレクラールビオロギー | 2'-0-alkyl nucleotides and polymers containing such nucleotides |
| KR950032263A (en) * | 1994-04-27 | 1995-12-20 | 베르너 발데그 | Nucleosides and oligonucleotides with 2'-ether group |
| WO2003104250A1 (en) * | 2002-06-07 | 2003-12-18 | Kylix, B. V. | New compounds for modulating the activity of exchange proteins directly activated by camp (epacs) |
-
1989
- 1989-08-10 JP JP20563189A patent/JPH0372493A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07103150B2 (en) * | 1990-04-09 | 1995-11-08 | オイロペーイッシェス ラボラトリウム フュア モレクラールビオロギー | 2'-0-alkyl nucleotides and polymers containing such nucleotides |
| KR950032263A (en) * | 1994-04-27 | 1995-12-20 | 베르너 발데그 | Nucleosides and oligonucleotides with 2'-ether group |
| WO2003104250A1 (en) * | 2002-06-07 | 2003-12-18 | Kylix, B. V. | New compounds for modulating the activity of exchange proteins directly activated by camp (epacs) |
| JP2005532360A (en) * | 2002-06-07 | 2005-10-27 | キリックス・ベー・ヴェー | Novel compounds for modulating the activity of exchange protein (Epac) directly activated by cAMP |
| AU2003242672B2 (en) * | 2002-06-07 | 2009-12-17 | Universitair Medisch Centrum Utrecht | New compounds for modulating the activity of exhange proteins directly activated by camp (EPACS) |
| US7906491B2 (en) | 2002-06-07 | 2011-03-15 | Univisitair Medisch Centrum Utrecht | Compounds for modulating the activity of exchange proteins directly activated by cAMP (Epacs) |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU613724A3 (en) | Method of obtaining 8-thiomethyl-ergolines or salts thereof | |
| RU2074172C1 (en) | N-BENZYL-β-PHENYLISOSERIN-(2R,3S), METHOD FOR ITS PRODUCTION AND METHOD OF PRODUCTION OF ESTER OF b-PHENYLISOSERIN-(2R,3S) | |
| CN110511193A (en) | A kind of α-ketothioamide compound and its synthesis method | |
| JPH0372493A (en) | Production of 2'-o-substituted-adenosine-3',5'-cyclic phosphoric acid or its salt | |
| JP2515568B2 (en) | Novel thiazolidine derivative | |
| JPH058200B2 (en) | ||
| JP2637705B2 (en) | Method for producing benzoquinone derivatives | |
| JPS6053039B2 (en) | N-Acetyl/Iramic acid derivative and method for producing the same | |
| CA1297878C (en) | Process for the obtention of the ethyl ester of the apovincaminic acid | |
| JPH07116213B2 (en) | Novel N-6,2'-O-disubstituted-adenosine-3 ', 5'-cyclic phosphate and process for producing the same | |
| US4438276A (en) | Process for synthesizing N-isopropyl-N'-o-carbomethoxyphenylsulphamide | |
| SU1270153A1 (en) | 5'-0-tritolmethyl derivatives of 2'-desoxynucleosides as starting substances in synthesis of oligonucleotides | |
| JPS61172846A (en) | Method of optical resolution of (+-)-2-chloroprorionic acid | |
| JPH0764868B2 (en) | Novel N 6 above, N 6 above, 2'-0-tri-substituted-adenosine-3 ', 5'-cyclic phosphate and process for producing the same | |
| CN107629039A (en) | The preparation method and intermediate of deuterated acrylamide | |
| JPS6152839B2 (en) | ||
| JPS6140669B2 (en) | ||
| JPH0692988A (en) | Method for synthesizing 2,2'-anhydroarabinosylthymine derivative | |
| JPS5872599A (en) | Conjugated glycoside derivative | |
| CN114478454A (en) | SGLT2 inhibitor key intermediate and preparation method thereof | |
| JPS609512B2 (en) | Method for producing 1,3-bis(2-tetrahydropyranyl)-5-fluorouracil | |
| JPH0798833B2 (en) | 2'-Bromo-2 ', 3'-didehydro-2', 3'-dideoxycytidine and process for producing the same | |
| JPS6219598A (en) | 2,3,2',3'-tetra-O-alkyl-α,α-trehalose derivative | |
| JP2920212B1 (en) | Method for producing 1,3-dioxolan-4-one compound | |
| BE828646A (en) | NEWS 1,4 - BENZODIAZEPINES AND METHODS FOR THEIR PREPARATIONS |